Latest Rejuve.AI (RJV) News Update

Deep Dive

1. Sentiment Overview

Traders express frustration over RJV’s underperformance vs. AI crypto peers (-64.7% YoY vs. sector average -22% (CoinMarketCap)), though some view the 90-day 1.1% gain as tentative stabilization. Long-term holders emphasize its real-world healthcare partnerships but acknowledge adoption could take years.

The 34.8% 24h volume spike to $1.3M suggests renewed speculative interest, but the $3.7M market cap and 0.355 turnover ratio signal thin liquidity – trades >$50K could cause 10%+ price swings.

2. Key Discussion Themes

• Use case scrutiny: Supporters highlight RJV’s medical data monetization model (Rejuve.AI whitepaper), while skeptics note competing projects (e.g., VitaDAO) have larger research war chests.
• Token utility doubts: Only 56.5% of the 1B max supply is circulating, with no recent burns or buybacks announced.
• Macro sensitivity: RJV’s 30-day 0.12% gain lags Bitcoin’s 11.7% rise, reflecting altcoins’ struggle during “Bitcoin Season” (CMC Altcoin Season Index: 23/100).

Conclusion

RJV’s niche AI/healthcare narrative hasn’t offset weak liquidity and concentrated ownership, but patient investors see multi-year potential if medical data partnerships materialize. Will Q3 2025 protocol upgrades improve tokenomics and attract institutional healthtech players?